Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Area of Science:

• Oncology
• Dermatology
• Cancer Research

Background:

• The National Comprehensive Cancer Network (NCCN) Guidelines for cutaneous melanoma undergo regular updates based on new clinical trial data.
• Recent advancements in immunotherapy and targeted therapy have profoundly impacted treatment strategies for melanoma.
• Existing guidelines required revision to incorporate these emerging therapeutic options.

Purpose of the Study:

• To summarize the key data and scientific rationale behind recent significant revisions to the NCCN Guidelines for cutaneous melanoma.
• To provide an overview of the updated recommendations for systemic therapy in resected and advanced melanoma.
• To highlight changes in treatment algorithms for melanoma based on immune checkpoint inhibitors and BRAF-targeted agents.

Main Methods:

• Review of pivotal clinical trials and real-world evidence informing systemic therapy in melanoma.
• Analysis of data supporting the efficacy and safety of immune checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4).
• Evaluation of data supporting BRAF-targeted therapies (e.g., BRAF and MEK inhibitors) in relevant melanoma patient populations.

Main Results:

• Significant revisions to adjuvant therapy recommendations for resected melanoma, incorporating immunotherapy and targeted agents.
• Updated treatment algorithms for unresectable or distant metastatic melanoma, emphasizing systemic therapy options.
• Evidence supporting improved outcomes with novel systemic therapies in various melanoma subtypes and stages.

Conclusions:

• The NCCN Guidelines for cutaneous melanoma have been substantially updated to reflect advances in systemic therapy.
• Immune checkpoint inhibitors and BRAF-targeted therapies are now integral components of both adjuvant and advanced melanoma treatment.
• These guideline revisions aim to optimize patient care and outcomes in cutaneous melanoma management.